BriaCell Therapeutics Says Bria-OTS Clears Safety Evaluation In Phase 1/2 Monotherapy Study And Now Transitions To Dosing Patients In Combination With Checkpoint Inhibitor

Author: Benzinga Newsdesk | May 27, 2025 06:34am

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, TSX:BCT), a clinical-stage biotechnology company advancing personalized immunotherapies for cancer, today announced that Bria-OTS has cleared its safety evaluation in the Phase 1/2 monotherapy study and has now transitioned to dosing patients in combination with a checkpoint inhibitor (CPI). The first patient has been dosed in the checkpoint inhibitor combination cohort of the ongoing Phase 1/2 study of Bria-OTS (NCT06471673) in metastatic breast cancer.

Bria-OTS, a personalized next-generation version of Bria-IMT™—currently in a pivotal Phase 3 trial—is designed to enhance immune responses against tumors. The CPI combination cohort follows the successful completion of a three-patient monotherapy safety run-in. Notably, the first monotherapy patient remains on study with complete resolution of lung metastasis.

Posted In: BCTX TSX:BCT